活体肾供体评估中肾小球滤过率（GFR）和蛋白尿评估策略。
Strategies for assessing GFR and albuminuria in the living kidney donor evaluation.
作者信息
Inker Lesley A, Huang Naya, Levey Andrew S
机构信息
Tufts Medical Center, Boston, MA, USA.
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
出版信息
Curr Transplant Rep. 2017 Mar;4(1):13-23. doi: 10.1007/s40472-017-0134-0. Epub 2017 Jan 29.
PURPOSE OF REVIEW
The international guideline development group Kidney Disease Improving Global Outcomes (KDIGO) recently published a comprehensive set of recommendations for living donor evaluation which contains a new framework for decision making in the evaluation of kidney donor candidates.
RECENT FINDINGS
The guidelines recommend that decisions to accept or decline a candidate donor should be based on incorporation of multiple sources of information pertaining to the donor candidate's likelihood of serious adverse outcomes after donation. Two central components of assessment of risk are glomerular filtration rate (GFR) and albuminuria. We describe strategies for clinical decision making in assessment of GFR and albuminuria in the evaluation of living kidney donor candidates. Our premise is that all measurements will contain error; no single test result should lead to a decision to accept or decline a donor candidate.
SUMMARY
A structured apporach to use of information from multiple sources (e.g. estimated and measured GFR, estimated and measured albuminuria) aids in test interpretation and can lead to increased accuracy of testing and efficiency of evaluation strategies.
综述目的
国际指南制定小组改善全球肾脏病预后组织（KDIGO）最近发布了一套全面的活体供体评估建议，其中包含了评估肾脏供体候选人的新决策框架。
最新发现
指南建议，接受或拒绝候选供体的决定应基于整合与候选供体捐赠后发生严重不良后果可能性相关的多种信息来源。风险评估的两个核心要素是肾小球滤过率（GFR）和蛋白尿。我们描述了在评估活体肾脏供体候选人时评估GFR和蛋白尿的临床决策策略。我们的前提是所有测量都将存在误差；不应仅凭单一检测结果就决定接受或拒绝候选供体。
总结
采用结构化方法利用多种信息来源（如估算和测量的GFR、估算和测量的蛋白尿）有助于检测结果的解读，并可提高检测准确性和评估策略的效率。
Zotero 插件